A Study of PRN1008 in Adult Patients With Pemphigus Vulgaris

Summary

Open-label cohort study in adult patients with newly diagnosed or relapsing pemphigus vulgaris, with intra-patient dose-adjustment based on clinical response and BTK occupancy, and with conventional immunosuppressive "rescue treatment", if indicated. The duration of therapy in Part A will be 12 weeks, followed by 12 weeks of follow up. The extension phase, Part B includes 24 weeks of therapy, followed by 4 weeks of follow-up.

Timeline

Start

2016-01-22

Primary completion

2019-12-18

Completion

2020-01-10

Drugs

Indications